Cargando…
Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader–Willi syndrome
Prader–Willi syndrome (PWS) is characterized by a switch from failure to thrive to excessive weight gain and hyperphagia in early childhood. Hyperghrelinemia may be involved in the underlying mechanisms of the switch. The purpose of this study is to evaluate acylated ghrelin (AG) and unacylated ghre...
Autores principales: | Kuppens, R. J., Diène, G., Bakker, N. E., Molinas, C., Faye, S., Nicolino, M., Bernoux, D., Delhanty, P. J. D., van der Lely, A. J., Allas, S., Julien, M., Delale, T., Tauber, M., Hokken-Koelega, A. C. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662713/ https://www.ncbi.nlm.nih.gov/pubmed/25989955 http://dx.doi.org/10.1007/s12020-015-0614-x |
Ejemplares similares
-
High unacylated ghrelin levels support the concept of anorexia in infants with prader-willi syndrome
por: Beauloye, Veronique, et al.
Publicado: (2016) -
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
por: Allas, Soraya, et al.
Publicado: (2018) -
SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome
por: Harisseh, Rania, et al.
Publicado: (2020) -
SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome
por: Allas, Soraya, et al.
Publicado: (2019) -
Is ghrelin a biomarker of early-onset scoliosis in children with Prader–Willi syndrome?
por: Pacoricona Alfaro, Dibia Liz, et al.
Publicado: (2021)